We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 16 MAY 2024
Ophthalmic, Parenteral, & Otic Drug Development: Does FDA's Draft Guidance Provide A Vehicle To Avoid Patent Problems?
Upadhye Tang
In April 2022, FDA released a proposed draft guidance (FDA Dock. No. 2022-D-0108) involving pH adjusters in drug development relating to ophthalmic, parenteral, or otic drug products.
United StatesIntellectual Property









